Skip to main content

Evidence From Two Parallel Depression Trials

The adoption of the Decentralized Clinical Trial model in psychiatry has been tempered by concern regarding the conduct of clinician-reported outcomes conducted by centralized raters. This is despite a history of successful deployment across a variety of psychiatric indications.

Boehringer Ingelheim (BI) partnered with Science 37 to conduct the first-ever fully decentralized trial studying BI 1358894 in treatment-resistant major depression (DCT). Concurrently, BI conducted a nearly identical global site-based trial (TRAD). This offered a unique opportunity to collaborate with Signant Health to report on quality of depression symptom assessment, using MADRS, conducted remotely in comparison to a parallel site-based trial.

Download the poster presentation to review the research findings.


This poster will be presented at the CNS Summit 2022 by Dr. Christopher Reist on Saturday, November 19th, 2022 at 5pm.